Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Domenica LorussoGiuseppa MalteseIlaria SabatucciSara CrestaCristina MatteoTommaso CerutiMaurizio D'IncalciMassimo ZucchettiFrancesco RaspagliesiCristina SonettoValentina SinnoDominique RonzulliSerena GiolittoFilippo de BraudPublished in: Targeted oncology (2020)
ClinicalTrials.gov identifier NCT03462212; registered March 2018.
Keyphrases